EX-10.13.1



 Exhibit 10.13.1 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 PUBLIC HEALTH SERVICE 
 FIRST AMENDMENT TO PATENT LICENSE AGREEMENT — EXCLUSIVE 
 (LICENSE NUMBER: L-127-2007/0) 
 (AMENDMENT NUMBER: L-127-2007/1) 
 This is the first amendment (“First Amendment”) of the Patent License Agreement—Exclusive by and between the National Institutes of Health (“NIH”) or the Food
and Drug Administration (“FDA”), hereinafter singly or collectively referred to as agencies of the United States Public Health Service (“PHS”) within the Department of Health and Human Services
(“HHS”), and GlobeImmune, Inc., having an effective date of June 12, 2007 and having NIH Reference Number L-127-2007/0
(“Agreement”). This First Amendment, having NIH Reference Number L-127-2007/1, is made between the PHS through the Office of
Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and GlobeImmune, Inc., having an office at 1450 Infinite Drive, Louisville, Colorado 80027
(“Licensee”). This First Amendment includes, in addition to the amendments made below, a Signature Page. 
 WHEREAS,
PHS and Licensee desire that the Agreement be amended a first time as set forth below. 
 NOW, THEREFORE, in consideration
of the mutual covenants and promises contained herein, PHS and Licensee, intending to be bound, hereby mutually agree to the following: 
  

	1)	The paragraphs on the cover page under the subheading titled “Serial Number(s) of Licensed Patent(s) or Patent Application(s):” and the paragraphs in
Appendix A under the subheading “Patent(s) or Patent Applications(s)” of the Agreement shall be deleted in their entirety and replaced with the following:[*] 


 

	2)	Paragraph 4.1 Shall be deleted and replaced with the following: 

 Upon written approval by PHS, Licensee and any sublicensees of patent rights under this Agreement may enter into sublicensing agreements under the Licensed Patent Rights, such
approval will not be unreasonably delayed or withheld, unless the provisions set forth in Paragraph 4.2 below are not included and/or otherwise made binding upon the sublicensee. For purposes of clarification, PHS agrees that modification of
the terms of this Agreement will not be a condition for approval by PHS for Licensee or any sublicensee to enter into sublicensing agreements. 
 Licensee shall provide written notice to PHS in the event Licensee or any sublicensee desires to grant a sublicense to a third party to develop or commercialize a Licensed
Product. In the event that PHS does not provide a written objection to Licensee within ten (10) business days after receiving notice under the preceding sentence, PHS shall be deemed to have given its approval to the
sublicense arrangement described in the notice. 
  

	3)	Paragraph 4.2 shall be deleted and replaced with the following: 

 Licensee agrees that any sublicenses granted by it or any sublicensee shall provide that the obligations to PHS of paragraphs 5.1-5.4, 8.1, 10,1,
10.2, 12.5 and 13.7-13.9 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement. Licensee further agrees to provide copies of these Paragraphs to all sublicense agreements. 

 

	4)	Paragraph 4.4 shall be deleted and replaced with the following; 


 

  

					
	 A-260-2009

 
 CONFIDENTIAL
 First Amendment of L-127-2007/0
 Model 09-2006 (updated 1-2008)
	  	 GlobeImmune, Inc.
 Page 1 of 4
	  	 March 26, 2010
 L-127-2007/1










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Licensee agrees to forward
to PHS a complete copy of each fully executed sublicense agreement entered into by Licensee or any sublicensee, postmarked within thirty (30) days of the execution of such agreement. To the extent permitted by law. PHS
agrees to maintain each such sublicense agreement in confidence. 
  

	5)	Within sixty (60) days of the execution of this First Amendment, Licensee shall pay PHS an amendment issue royalty in the sum of Seven
Thousand Five Hundred US Dollars ($7,500), to be sent to the address specified in Attachment 1. 

  

	6)	The following shall he deleted from Appendix C of the Agreement: 

 V. Licensee agrees to pay PHS [*] royalties of [*] 
  

	7)	The following shall be added to Appendix C of the Agreement: 

 V. Licensee agrees to pay PHS [*] royalties of [*] 
  

	8)	In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1, such provision(s) is/are hereby amended to the extent required to avoid
such inconsistency and to give effect to the payment information in such Attachment 1. 

  

	9)	All terms and conditions of the Agreement not herein amended remain binding and in effect. 


 

	10)	The terms and conditions of this First Amendment shall, at PHS’ sole option, be considered by PHS to be withdrawn from Licensee’s
consideration and the terms and conditions of this First Amendment, and the First Amendment itself to be null and void, unless this First Amendment is executed by the Licensee and a fully executed original is received by
PHS within sixty (60) days from the date of PHS signature found at the Signature Page. 

  

	11)	This First Amendment is effective upon execution by all parties. 

 SIGNATURES BEGIN ON NEXT PAGE 
  

  

					
	 A-260-2009

 
 CONFIDENTIAL
 First Amendment of L-127-2007/0
 Model 09-2006 (updated 1-2008)
	  	 GlobeImmune, Inc.
 Page 2 of 4
	  	 March 26, 2010
 L-127-2007/1










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 FIRST AMENDMENT TO
PATENT LICENSE AGREEMENT — EXCLUSIVE 
 (LICENSE NUMBER: L-127-2007/0) 
 (AMENDMENT NUMBER: L-127-2007/1) 
 SIGNATURE PAGE

 In Witness Whereof, the parties have executed this First Amendment on the dates set forth below. 

 

					
	For PHS:	 		 	
			
	/s/ Richard U. Rodriguez	 		 	3-30-10
	 Richard U. Rodriguez
 Director,
Division of Technology Development and Transfer
 Office of Technology Transfer
 National Institutes of Health
	 		 	Date

  

					
			
	For GlobeImmune:	 		 	
			
	 /s/ Jeff Rona
	 		 	4/5/10
	 Jeff Rona

Chief Business Officer

GlobeImmune, Inc.
	 		 	Date

  

  

					
	 A-260-2009

 
 CONFIDENTIAL
 First Amendment of L-127-2007/0
 Model 09-2006 (updated 1-2008)
	  	 GlobeImmune, Inc.
 Page 3 of 4
	  	 March 26, 2010
 L-127-2007/1










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 ATTACHMENT 1 –
ROYALTY PAYMENT OPTIONS 
 NIH/PHS License Agreements 
 *In order to process payment via Electronic Funds Transfer sender MUST supply the following information: 
 Procedure for Transfer of Electronic Funds to NIH Royalty Payments 
 [*] 

Checks drawn on a US, bank account should be sent directly to the following address: 

National Institutes of Health (NIH) 
 P.O. Box
979071 
 St. Louis, MO 63197-9000 

Overnight or courier deliveries should be sent to the following address: 
 US Bank 
 Government Lockbox
SL-MO-C2GL 
 1005 Convention Plaza 

St. Louis, MO 63101 
 Phone: 314-418-4087 
 Checks drawn on a foreign bank account should be
sent directly to the following address: 
 National Institutes of Health (NIH) 
 Office of Technology Transfer 
 Royalties Administration Unit 

6011 Executive Boulevard 
 Suite 325, MSC 7660

 Rockville, Maryland 20852 
 Phone: 301-496-7057 
 All checks should be made payable to “NIH
Patent Licensing”. 
 The OTT Reference Number MUST appear on checks, reports and correspondence 

 

  

					
	 A-260-2009

 
 CONFIDENTIAL
 First Amendment of L-127-2007/0
 Model 09-2006 (updated 1-2008)
	  	 GlobeImmune, Inc.
 Page 4 of 4
	  	 March 26, 2010
 L-127-2007/1